1.rhBMP-2-Conjugated Three-Dimensional-Printed Poly(L-lactide) Scaffold is an Effective Bone Substitute
Yu Ri HONG ; Tae-Ho KIM ; Kyeong-Hyeon PARK ; Jumi KANG ; Kyueui LEE ; Eui Kyun PARK ; Tae-Geon KWON ; Jeong Ok LIM ; Chang-Wug OH
Tissue Engineering and Regenerative Medicine 2023;20(1):69-81
BACKGROUND:
Bone growth factors, particularly bone morphogenic protein-2 (BMP-2), are required for effective treatment of significant bone loss. Despite the extensive development of bone substitutes, much remains to be desired for wider application in clinical settings. The currently available bone substitutes cannot sustain prolonged BMP-2 release and are inconvenient to use. In this study, we developed a ready-to-use bone substitute by sequential conjugation of BMP to a three-dimensional (3D) poly(L-lactide) (PLLA) scaffold using novel molecular adhesive materials that reduced the operation time and sustained prolonged BMP release.
METHODS:
A 3D PLLA scaffold was printed and BMP-2 was conjugated with alginate-catechol and collagen. PLLA scaffolds were conjugated with different concentrations of BMP-2 and evaluated for bone regeneration in vitro and in vivo using a mouse calvarial model. The BMP-2 release kinetics were analyzed using ELISA. Histological analysis and microCT image analysis were performed to evaluate new bone formation.
RESULTS:
The 3D structure of the PLLA scaffold had a pore size of 400 lm and grid thickness of 187–230 lm. BMP-2 was released in an initial burst, followed by a sustained release for 14 days. Released BMP-2 maintained osteoinductivity in vitro and in vivo. Micro-computed tomography and histological findings demonstrate that the PLLA scaffold conjugated with 2 lg/ml of BMP-2 induced optimal bone regeneration.
CONCLUSION
The 3D-printed PLLA scaffold conjugated with BMP-2 enhanced bone regeneration, demonstrating its potential as a novel bone substitute.
2.Differences in Acetabular Morphology Related to Sex and Side in South Korean Population
Chaemoon LIM ; Young Ho ROH ; Jun Eui HONG ; Kwang Woo NAM
Clinics in Orthopedic Surgery 2022;14(4):486-492
Background:
The normal references for acetabular parameters are important for the diagnosis of hip diseases and planning of total hip arthroplasty. There are wide interindividual differences in acetabular morphology in the normal population, and little is known about differences in acetabular morphology in the average South Korean population. The purpose of this study was to evaluate side and sex differences in acetabular morphology in the South Korean population.
Methods:
The acetabular parameters, including anteversion angle, abduction angle, center-edge angle, acetabular width and depth, and acetabular-head index, were measured on three-dimensional computed tomography images in 197 healthy Korean adults. Differences in acetabular parameters according to side and sex were evaluated.
Results:
The mean acetabular anteversion angle of men and women was 17.3° ± 5.2° and 20.1° ± 3.5°, respectively. The mean acetabular width of men and women was 61.5 ± 4.6 cm and 56.5 ± 4.0 cm, respectively. There were significant sex differences in acetabular anteversion angle (p = 0.001) and acetabular width (p = 0.036) when adjusted for age, body height, and weight. The mean acetabular width of the right side and the left side was 60.2 ± 5.2 cm and 57.8 ± 4.5 cm, respectively. There were significant side differences in acetabular width (p = 0.007) when adjusted for age, body height, weight, and sex.
Conclusions
Differences and reference ranges of acetabular parameters are important for the diagnosis of acetabular deformity, such as femoroacetabular impingement and acetabular dysplasia. Moreover, these differences and reference ranges are useful for preoperative planning and safe positioning of acetabular components in total hip arthroplasty.
3.The Neuropeptide Spexin Promotes the Osteoblast Differentiation of MC3T3-E1 Cells via the MEK/ERK Pathway and Bone Regeneration in a Mouse Calvarial Defect Model
Freshet ASSEFA ; Ju Ang KIM ; Jiwon LIM ; Sang-Hyeon NAM ; Hong-In SHIN ; Eui Kyun PARK
Tissue Engineering and Regenerative Medicine 2022;19(1):189-202
BACKGROUND:
The neural regulation of bone regeneration has emerged recently. Spexin (SPX) is a novel neuropeptide and regulates multiple biological functions. However, the effects of SPX on osteogenic differentiation need to be further investigated. Therefore, the aim of this study is to investigate the effects of SPX on osteogenic differentiation, possible underlying mechanisms, and bone regeneration.
METHODS:
In this study, MC3T3-E1 cells were treated with various concentrations of SPX. Cell proliferation, osteogenic differentiation marker expressions, alkaline phosphatase (ALP) activity, and mineralization were evaluated using the CCK-8 assay, reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR), ALP staining, and alizarin red S staining, respectively. To determine the underlying molecular mechanism of SPX, the phosphorylation levels of signaling molecules were examined via western blot analysis. Moreover, in vivo bone regeneration by SPX (0.5 and 1 lg/ll) was evaluated in a calvarial defect model. New bone formation was analyzed using micro-computed tomography (micro-CT) and histology.
RESULTS:
The results indicated that cell proliferation was not affected by SPX. However, SPX significantly increased ALP activity, mineralization, and the expression of genes for osteogenic differentiation markers, including runt-related transcription factor 2 (Runx2), Alp, collagen alpha-1(I) chain (Col1a1), osteocalcin (Oc), and bone sialoprotein (Bsp). In contrast, SPX downregulated the expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1). Moreover, SPX upregulated phosphorylated mitogen-activated protein kinase kinase (MEK1/2) and extracellular signal-regulated kinase (ERK1/2). in vivo studies, micro-CT and histologic analysis revealed that SPX markedly increased a new bone formation.
CONCLUSION
Overall, these results demonstrated that SPX stimulated osteogenic differentiation in vitro and increased in vivo bone regeneration via the MEK/ERK pathway.
4.The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01
Young Zoon KIM ; Chae Yong KIM ; Jaejoon LIM ; Kyoung Su SUNG ; Jihae LEE ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Tae Hoon ROH ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Chan Woo WEE ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Je Beom HONG ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(1):1-9
BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient.
Brain
;
Central Nervous System
;
Chemoradiotherapy
;
Diagnosis
;
Drug Therapy
;
Glioblastoma
;
Humans
;
Korea
;
Radiotherapy
5.Survey of Gymnophalloides seoi Metacercariae in Natural and Cultured Oysters from Several Western Coastal Areas, Korea
Taehee CHANG ; Bong Kwang JUNG ; Hyemi SONG ; Jaeeun CHO ; Sooji HONG ; Keon Hoon LEE ; Eui Hyug HOANG ; Jisu KANG ; Jini LIM ; Hana LEE ; Jong Yil CHAI
The Korean Journal of Parasitology 2019;57(6):705-708
Gymnophalloides seoi (Digenea: Gymnophallidae) is a human intestinal trematode contracted by eating raw oysters (Crassostrea gigas) in the Republic of Korea (=Korea). It has been known to be highly endemic in Aphae Island, Shinan-gun, Jeollanam-do (Province). However, recent epidemiological status of G. seoi has not been reported since the 1990s. In this study, we investigated the prevalence of G. seoi metacercariae in natural and cultured oysters collected from 3 islands and 2 coastal areas in western parts of Korea. The oysters were examined using the artificial digestion method followed by stereomicroscopy. The overall positive rate of G. seoi metacercariae in natural oysters was 66.0% (99/150), and the oysters collected from Yubu Island showed the highest infection rate (74.0%). However, the metacercarial density per oyster was relatively low (1.5–2.4 per oyster). By contrast, no metacercaria was found in cultured oysters purchased from 2 coastal areas in Chungcheongnam-do. Thus, we could confirm that natural oysters produced from 3 western coastal islands are infected with G. seoi metacercariae, whereas cultured oysters purchased from 2 coastal areas were free from infection.
Chungcheongnam-do
;
Digestion
;
Eating
;
Humans
;
Islands
;
Jeollanam-do
;
Korea
;
Metacercariae
;
Methods
;
Ostreidae
;
Prevalence
;
Republic of Korea
6.The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
Young Zoon KIM ; Chae Yong KIM ; Chan Woo WEE ; Tae Hoon ROH ; Je Beom HONG ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Kyoung Su SUNG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Jihae LEE ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Jaejoon LIM ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(2):74-84
BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults. RESULTS: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group. CONCLUSION: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
Adult
;
Astrocytoma
;
Brain
;
Central Nervous System
;
Drug Therapy
;
Drug Therapy, Combination
;
Follow-Up Studies
;
Glioblastoma
;
Glioma
;
Humans
;
Isocitrate Dehydrogenase
;
Korea
;
Oligodendroglioma
;
Radiotherapy
;
World Health Organization
7.The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01
Young Zoon KIM ; Chae Yong KIM ; Jaejoon LIM ; Kyoung Su SUNG ; Jihae LEE ; Hyuk Jin OH ; Seok Gu KANG ; Shin Hyuk KANG ; Doo Sik KONG ; Sung Hwan KIM ; Se Hyuk KIM ; Se Hoon KIM ; Yu Jung KIM ; Eui Hyun KIM ; In Ah KIM ; Ho Sung KIM ; Tae Hoon ROH ; Jae Sung PARK ; Hyun Jin PARK ; Sang Woo SONG ; Seung Ho YANG ; Wan Soo YOON ; Hong In YOON ; Soon Tae LEE ; Sea Won LEE ; Youn Soo LEE ; Chan Woo WEE ; Jong Hee CHANG ; Tae Young JUNG ; Hye Lim JUNG ; Jae Ho CHO ; Seung Hong CHOI ; Hyoung Soo CHOI ; Je Beom HONG ; Do Hoon LIM ; Dong Sup CHUNG ;
Brain Tumor Research and Treatment 2019;7(2):63-73
BACKGROUND: There was no practical guideline for the management of patients with central nervous system tumor in Korea in the past. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, developed the guideline for glioblastoma successfully and published it in Brain Tumor Research and Treatment, the official journal of KSNO, in April 2019. Recently, the KSNO guideline for World Health Organization (WHO) grade III cerebral glioma in adults has been established. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searches in PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords. Scope of the disease was confined to cerebral anaplastic astrocytoma and oligodendroglioma in adults. RESULTS: Whenever radiological feature suggests high grade glioma, maximal safe resection if feasible is globally recommended. After molecular and histological examinations, patients with anaplastic astrocytoma, isocitrate dehydrogenase (IDH)-mutant should be primary treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy whereas those with anaplastic astrocytoma, NOS, and anaplastic astrocytoma, IDH-wildtype should be treated following the protocol for glioblastomas. In terms of anaplastic oligodendroglioma, IDH-mutant and 1p19q-codeletion, and anaplastic oligodendroglioma, NOS should be primary treated by standard brain radiotherapy and neoadjuvant or adjuvant PCV (procarbazine, lomustine, and vincristine) combination chemotherapy. CONCLUSION: The KSNO's guideline recommends that WHO grade III cerebral glioma of adults should be treated by maximal safe resection if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors.
Adult
;
Astrocytoma
;
Brain
;
Brain Neoplasms
;
Central Nervous System
;
Drug Therapy
;
Drug Therapy, Combination
;
Glioblastoma
;
Glioma
;
Humans
;
Isocitrate Dehydrogenase
;
Korea
;
Lomustine
;
Oligodendroglioma
;
Radiotherapy
;
World Health Organization
8.Significant Abnormalities Other than Lung Cancer in Korean Lung Cancer CT Screening
Soon Ho YOON ; Junghee HONG ; Eui Jin HWANG ; Heekyung KIM ; Hyun ju LIM ; Young Joo SUH ; Hyae Young KIM ; Jin Mo GOO
Journal of the Korean Radiological Society 2019;80(5):837-848
A low-dose chest CT is performed for early detection of lung cancer, but the CT scan frequently shows several incidental abnormalities. Identification of the incidental findings may enable early detection of diseases other than lung cancer, thereby improving the survival of the individual undergoing screening. However, insignificant incidental abnormalities may cause unnecessary additional examination and costs. It is crucial for radiologists to appropriately comprehend and report significant incidental abnormalities other than lung cancer for successful implementation of the national lung cancer screening program in Korea.
9.Morphological and Molecular Characterization of Toxocara tanuki (Nematoda: Ascaridae) from Korean Raccoon Dog, Nyctereutes procyonoides koreensis
Umanets ALEXANDER ; Chae Wong LIM ; Bumseok KIM ; Eui Ju HONG ; Hyeon Cheol KIM ; Bae Keun PARK
The Korean Journal of Parasitology 2018;56(6):567-575
Present study was performed to describe the morphological and molecular characterization of Toxocara tanuki (Nematoda: Ascaridae) from Korean raccoon dog, Nyctereutes procyonoides koreensis, naturally infected in the Republic of Korea (Korea). Juvenile and adult worms of T. tanuki were recovered in 5 out of 10 raccoon dogs examined and the larval worms were detected in 15 out of 20 muscle samples (75%). Small lateral alae were observed on the cranial end of the body in male and female adults and 2 long spicules (3.0–3.5 mm) were characteristically observed in the posterior end of males. In SEM observation, 18 pairs of proximal precloacal, a precloacal median, a postcloacal median and 5 pairs of postcloacal papillae were uniquely revealed in the posterior portion of males, but the proximal papillae were not shown in the lateral ends of females. Molecular analysis on the 18S rRNA partial DNA sequences was revealed the same finding in both samples, adult worms and muscle larvae, which are closely related to T. tanuki. In conclusion, it was confirmed for the first time that T. tanuki is indigenously distributed, the Korean raccoon dog is acted as the natural definitive host of this nematode in Korea and the morphological characteristics of T. tanuki were shown in specific structure for single postcloacal median papilla in male.
Adult
;
Base Sequence
;
Female
;
Humans
;
Korea
;
Larva
;
Larva Migrans
;
Male
;
Raccoon Dogs
;
Raccoons
;
Republic of Korea
;
Toxocara
10.Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Byung Sup KIM ; Ho Jun SEOL ; Do Hyun NAM ; Chul Kee PARK ; Il Han KIM ; Tae Min KIM ; Jeong Hoon KIM ; Young Hyun CHO ; Sang Min YOON ; Jong Hee CHANG ; Seok Gu KANG ; Eui Hyun KIM ; Chang Ok SUH ; Tae Young JUNG ; Kyung Hwa LEE ; Chae Yong KIM ; In Ah KIM ; Chang Ki HONG ; Heon YOO ; Jin Hee KIM ; Shin Hyuk KANG ; Min Kyu KANG ; Eun Young KIM ; Sun Hwan KIM ; Dong Sup CHUNG ; Sun Chul HWANG ; Joon Ho SONG ; Sung Jin CHO ; Sun Il LEE ; Youn Soo LEE ; Kook Jin AHN ; Se Hoon KIM ; Do Hun LIM ; Ho Shin GWAK ; Se Hoon LEE ; Yong Kil HONG
Cancer Research and Treatment 2017;49(1):193-203
PURPOSE: The purpose of this study was to investigate the feasibility and survival benefits of combined treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. MATERIALS AND METHODS: A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January 2006 until June 2011, were analyzed retrospectively. RESULTS: After the first operation, a gross total resection (GTR), subtotal resection (STR), partial resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. The methylation status of O6-methylguanine-DNA methyltransferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up period was 16.3 months and the median overall survival (OS) was 17.5 months. The actuarial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively. The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-, 3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy alone, regardless of the methylation status of the MGMT promoter. Patients with a methylated MGMT promoter also showed a significantly longer OS and PFS than those with an unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2% during the adjuvant TMZ period. CONCLUSION: Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and tolerable toxicity than those who did not undergo this treatment.
Biopsy
;
Chemoradiotherapy*
;
Disease-Free Survival
;
Follow-Up Studies
;
Glioblastoma*
;
Humans
;
Korea*
;
Methylation
;
Radiotherapy
;
Retrospective Studies*
;
Survival Rate

Result Analysis
Print
Save
E-mail